Adjuvant Chemotherapy for Epithelial Ovarian Cancer (EOC)

Lalit Kumar; Roopa Hari Prasad; Manju Sengar

doi:10.1055/s-0041-1733142

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2006; 27(01): 4-5
DOI: 10.1055/s-0041-1733142

Editorial

Adjuvant Chemotherapy for Epithelial Ovarian Cancer (EOC)

Authors

Lalit Kumar

Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India
Roopa Hari Prasad

Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India
Manju Sengar

Department of Medical Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India

Abstract

als PDF herunterladen

PDF (177 kb)

Referenzen

References
1 Cannistra SA. Cancer of ovary. N Eng J Med 2004;351:2519-2529.
2 Brislow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 2002;20:1248-1259.
3 McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Eng J Med 334;3-6,1996.
4 Piccart M, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin -paclitaxel versus cisplatin cyclophosphamide in women with advanced epithelial ovarian cancer : Three year results. J Nat Cancer Inst 2000;92:699-708.
5 The International Collaborative Ovarian Neoplasms (ICON) Group : Paclitaxel plus carboplatin versus standard chemotherapy with either single agent carboplatin or cyclophosphamide, doxorubicin and cisplatin in women with ovarian cancer. The ICON 3 randomized trial. Lancet 2002;360:505-515.
6 du Bois A, Luck HJ, Meier W Carboplatin plus paclitaxel as first-line chemotherapy in previously untreated advanced ovarian cancer. German AGO Study Group Ovarian Cancer. Arbeitsgemeinschaft Gynakologische Onkologie. Semin Oncol. 1997;24(4Suppl 11):S11-28-S11-33.
7 Lal P, Tiwari A, Rastogi N, & Kumar Sh. Epithelial ovarian cancer : an audit of patients treated over 15 years. Ind J Med & Paed Oncol 2006;27:15-22.
8 Junor EJ, Hole DJ, McNulty L, et al. Specialist gynecologists and survival outcome in ovarian cancer: A Scottish national study of 1866 patients. Br J Obstet Gynecol 1999;106:1130-1136.
9 Schwartz PE, Rutherford TJ, Chambers JT et al. Neoadjuvant chemotherapy for advanced ovarian cancer: Long term survival Gyneco Oncol 1999;72:93-99.
10 Vergote IB, de Wever I, decloedt J, Tjalma W, et al. Neoadjuvant chemotherapy versus primary debulking surgery in advanced ovarian cancer. Sem Oncol 2000;27(suppl.7):31-36.